Literature DB >> 21057316

Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome.

Jurjan Aman1, Melanie van der Heijden, Arthur van Lingen, Armand R J Girbes, Geerten P van Nieuw Amerongen, Victor W M van Hinsbergh, A B Johan Groeneveld.   

Abstract

OBJECTIVES: To evaluate the diagnostic value of plasma protein levels for pulmonary vascular permeability and acute respiratory distress syndrome. During acute lung injury and acute respiratory distress syndrome, increased vascular permeability induces protein-rich fluid extravasation. We hypothesized that plasma protein levels predict increased vascular permeability and acute respiratory distress syndrome.
DESIGN: A prospective, observational study. PATIENTS: Eighty-three consecutive, mechanically ventilated patients with or at risk for acute lung injury/acute respiratory distress syndrome, of whom 18 had sepsis. Patients with increased pulmonary capillary wedge pressures or central venous pressures were excluded.
INTERVENTIONS: Patients were subjected to pulmonary capillary wedge pressure/central venous pressure-guided fluid loading with saline or colloid fluids.
MEASUREMENTS AND MAIN RESULTS: We measured plasma albumin and transferrin levels and determined the Gallium-transferrin pulmonary leak index, the American European Consensus Conference criteria, and the lung injury score. Measurements were performed before and after fluid loading to evaluate effects of fluid loading. Plasma albumin and transferrin levels were approximately 30% lower in acute respiratory distress syndrome than patients with acute lung injury (p < .01) and patients without lung injury (p < .05). Protein levels inversely related to the pulmonary leak index (standardized regression coefficient -0.28, p < .001 for albumin; standardized regression coefficient -0.30, p = .003 for transferrin) and the lung injury score (standardized regression coefficient -0.19, p = .01 for albumin), independently of presence of sepsis, severity of disease, and fluid loading. Albumin and transferrin levels had a high sensitivity (77-93%) and negative predictive value (80-98%) for elevated pulmonary vascular permeability and acute respiratory distress syndrome (American European Consensus Conference criteria and lung injury score). The addition of hypoalbuminemia (<17.5 g/L) and hypotransferrinemia (<0.98 g/L) as criteria to the American European Consensus Conference criteria or the lung injury score increased their predictive values for elevated pulmonary vascular permeability.
CONCLUSIONS: In critically ill patients, decreased plasma albumin and transferrin levels parallel increased pulmonary vascular permeability irrespective of underlying disease and fluid status. While normal levels help to exclude acute respiratory distress syndrome, hypoalbuminemia and hypotransferrinemia increase the diagnostic accuracy of the American European Consensus Conference criteria and lung injury score for elevated pulmonary vascular permeability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21057316     DOI: 10.1097/CCM.0b013e3181feb46a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

Review 1.  Known and potential roles of transferrin in iron biology.

Authors:  Thomas Benedict Bartnikas
Journal:  Biometals       Date:  2012-08       Impact factor: 2.949

2.  Short-term inhalation of cadmium oxide nanoparticles alters pulmonary dynamics associated with lung injury, inflammation, and repair in a mouse model.

Authors:  Jason L Blum; Lauren K Rosenblum; Gabriele Grunig; Mary Beth Beasley; Judy Q Xiong; Judith T Zelikoff
Journal:  Inhal Toxicol       Date:  2014-01       Impact factor: 2.724

Review 3.  Biomarkers in acute lung injury--marking forward progress.

Authors:  Nicolas Barnett; Lorraine B Ware
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

4.  A retrospective analysis of 25% human serum albumin supplementation in hypoalbuminemic dogs with septic peritonitis.

Authors:  Farrah B Horowitz; Robyn L Read; Lisa L Powell
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

5.  Fructose-1,6-bisphosphate protects against Zymosan-induced acute lung injury in mice.

Authors:  Roberto Christ Vianna Santos; Rafael Noal Moresco; Miguel Angel Peña Rico; Antonio R García Susperregui; Jose Luis Rosa; Ramon Bartrons; Francesc Ventura; Débora Nunes Mário; Sydney Hartz Alves; Etiane Tatsch; Helena Kober; Ricardo Obalski de Mello; Patrícia Scherer; Jarbas Rodrigues de Oliveira
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

6.  Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant.

Authors:  Mary K Porteous; Bonnie Ky; James N Kirkpatrick; Russell Shinohara; Joshua M Diamond; Rupal J Shah; James C Lee; Jason D Christie; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

7.  Arctigenin attenuates lipopolysaccharide-induced acute lung injury in rats.

Authors:  Xianbao Shi; Hongzhi Sun; Dun Zhou; Huanjiu Xi; Lina Shan
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

8.  Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Jinqiu Qin; Yuanyuan Qin; Yangyang Wu; Aiqiu Wei; Meiling Luo; Lin Liao; Faquan Lin
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

9.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

10.  New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs.

Authors:  Matthias Seehase; Jennifer J P Collins; Elke Kuypers; Reint K Jellema; Daan R M G Ophelders; Olga L Ospina; J Perez-Gil; Federico Bianco; Raffaella Garzia; Roberta Razzetti; Boris W Kramer
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.